# US 2020/0399320 A1 · Chimeric Polypeptides and Uses Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0399320 A1
- Document ID: US20200399320A1
- Status: Published application
- Kind: A1
- Application number: 15/929,737
- Filed: 2020-05-19
- Published: 2020-12-24
- Earliest claimed: 2017-09-22
- Assignees: Kite Pharma, Inc.
- Applicants: Kite Pharma, Inc.
- Inventors: Jed J.W. WILTZIUS; Stuart A. SIEVERS
- Web page: https://patentgrep.com/patent/US20200399320A1

## CPC

- C07K 14/003: {Peptide-nucleic acids (PNAs)}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4211: {CD19 or B4}
- A61K 47/65: Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
- A61P 35/02: specific for leukemia
- C07K 4/00: Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
- C07K 7/06: having 5 to 11 amino acids
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 16/2803: {against the immunoglobulin superfamily}
- C07K 16/44: against material not provided for elsewhere {, e.g. haptens, metals, DNA, RNA, amino acids}
- C12N 15/62: DNA sequences coding for fusion proteins
- C12N 15/85: for animal cells
- C07K 2317/32: specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2319/40: containing a tag for immunodetection, or an epitope for immunisation
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention provides novel peptides (e.g., linkers) and polypeptide compositions comprising the linkers (e.g., fusion proteins) and methods of using the polypeptide compositions. Peptides (e.g., linkers) are useful as tags and for engineering fusion proteins (e.g., antigen binding molecules, scFv). Polypeptide linkers described herein facilitate flexibility of linked peptides allowing for proper folding, conformation and reduced immunogenicity.

## Claims

### Claim at position 1

1-14. (canceled)

### Claim 15

A fusion protein comprising:
a first polypeptide and a second polypeptide covalently linked by
a peptide comprising a consensus sequence GKPGSGZ,
wherein the peptide is 6-20 amino acids in length;
wherein Z is glycine (G) or a negatively charged amino acid; and
wherein the peptide is not GSTSGSGKPGSGEGSTKG (SEQ ID NO: 1), GSGKPGSGEG (SEQ ID NO: 13), GKPGSGEG (SEQ ID NO: 14), or SGKPGSGE (SEQ ID NO: 15).

### Claim 16 (depends on 15)

The fusion protein of claim 15, wherein the first polypeptide comprises a light chain variable domain and the second polypeptide comprises a heavy chain variable domain.

### Claim 17 (depends on 15)

A polynucleotide encoding the peptide according to claim 15.

### Claim 18 (depends on 15)

A polynucleotide encoding the fusion protein of claim 15.

### Claim 19 (depends on 18)

An expression vector comprising a polynucleotide of claim 18.

### Claim 20 (depends on 18)

A recombinant cell comprising a polynucleotide of claim 18.

### Claim 21 (depends on 15)

The fusion protein of claim 15, wherein the consensus sequence is GKPGSGG (SEQ ID NO: 6) or GSGKPGSGEGG (SEQ ID NO: 31).

### Claim 22 (depends on 15)

The fusion protein of claim 15, wherein the peptide is an amino acid sequence having at least 90% identity to any one of GGGSGKPGSGEGGGS (SEQ ID NO: 7), GGGSGKPGSGEGGGGS (SEQ ID NO: 8), GGGGSGKPGSGGGGS (SEQ ID NO: 9), GGGGSGKPGSGEGGS (SEQ ID NO: 10), GGGGSGKPGSGEGGGS (SEQ ID NO: 11), GGGGSGKPGSGEGGGGS (SEQ ID NO: 12), STSGSGKPGSGEGST (SEQ ID NO: 17),

### Claim 23 (depends on 15)

The fusion protein of claim 15, wherein the fusion protein is an antigen binding molecule.

### Claim 24 (depends on 20)

The recombinant cell of claim 20, wherein the cell is an immune cell.

### Claim 25 (depends on 24)

The immune cell of claim 24, wherein the immune cell is a T cell, NK cell, or a stem cell.